Briefly, the test determines if the PTEN gene is functioning properly, as it is a tumor suppressor gene that is linked with cell regulation. If patients have a low level of the protein, studies have shown a progression of the cancer, while if the levels remain higher, the less chances of...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
12-22-2008
Filed under:
Filed under: Medically Related, Insurance, Pharma/FDA News, personalized medicine, Genomics, healthcare, Cancer, tumors, Chemotherapy, markers, PTEN gene, Myriad, diagnositic tests
American Society of Clinical Oncology and Blue Cross/Blue Shield of Michigan will collect cancer information from 11 oncology practices in Michigan. Each physician will be paid around $3000.00 for their time in for the collection process. This is good for the exchange of information...